Pretorius et al 1 report that elevated plasminogen activator inhibitor-1 (PAI-1) levels are independent predictors of the development of atrial fibrillation (AF) after cardiopulmonary bypass, raising the possibility that postoperative AF is secondary to inflammation and fibrosis. PAI-1 also could promote myocardial remodeling by reducing matrix metalloproteinase activity because PAI-1 inhibits tissue plasminogen activator (tPA) and consequently plasmin, which is a potent activator of matrix metalloproteinases. There also is a link between fibrinolysis and inflammation, but elevated PAI-1 levels are part of various pathophysiological interactions. For example, elevated PAI-1 levels are found in the insulin resistance syndrome, so its prognostic value in different conditions often disappears after adjustment for body mass index, triglycerides, and high-density lipoprotein cholesterol. 2 As we have previously reviewed, the increased PAI-1 levels in AF have raised different hypotheses, including implications for thrombosis, endothelial damage/dysfunction, inflammation, or other confounders. 3 Elevated PAI-1 levels also are reported in patients with mitral stenosis, including those in sinus rhythm, 3 and more recently, high baseline PAI-1 activity has been shown to be a strong predictor of AF recurrence after electric cardioversion. 4 The different facets of PAI-1 in AF merit some discussion. The fibrinolytic system plays an important role in preventing intravascular thrombosis; hence, the fibrinolytic function in the vasculature is dependent on the rate of secretion of tPA, the inhibition of tPA by PAI-1 and other inhibitors, and the hepatic clearance of tPA. The improvement in fibrinolytic markers in AF after "steady-state" oral anticoagulation 3 supports the prothrombotic role of PAI-1.
